A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

计划入组 58 人 · 首次发布于 2026 年 6 月 11 日

C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

计划入组 1 人 · 首次发布于 2016 年 10 月 18 日

Felzartamab in Late Antibody-Mediated Rejection

计划入组 22 人 · 首次发布于 2021 年 8 月 25 日

HyperAcute Renal

Amniotic Suspension Allograft

Antilymphocyte immunoglobulin (horse)(Atgam)

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

River 3 Renal Corp.

United States

CASI Pharmaceuticals Surges 57% Following FDA Clearance for CID-103 Kidney Transplant Rejection Therapy

CASI Pharmaceuticals Names David Cory CEO to Advance Anti-CD38 Antibody CID-103 Program

CASI Pharmaceuticals' CID-103 Shows 73% Response Rate in Phase 1 Immune Thrombocytopenia Trial